@carnage4life 23andMe has previously licensed their pseudo-anonymized data to big pharma, which I imagine has been profitable. That said, without a steady stream of new samples to enhance the statistical value, it seems their business model for DNA sampling might face challenges. I wonder if, without ongoing data growth, this sale could end up being more of a one-off transaction or even an asset strip, rather than a sustainable long-term operation.